Neuroscience and NeuroanaesthesiaREMIFENTANIL (cas 132875-61-7) as an adjunct to anaesthesia for electroconvulsive therapy fails to confer long-term benefits
-
Add time:09/01/2019 Source:sciencedirect.com
BackgroundAdding the μ-opioid receptor agonist remifentanil to agents used to induce general anaesthesia in electroconvulsive therapy (ECT) can reduce the required doses of induction agents and their unfavourable effects on seizure threshold and quality. However, whether remifentanil has favourable long-term treatment effects in terms of response and remission rates, speed of response and remission, and side-effects has not been studied.
We also recommend Trading Suppliers and Manufacturers of REMIFENTANIL (cas 132875-61-7). Pls Click Website Link as below: cas 132875-61-7 suppliers
Prev:Annexin 1 inhibits REMIFENTANIL (cas 132875-61-7)-induced hyperalgesia and NMDA receptor phosphorylation via regulating spinal CXCL12/CXCR4 in rats
Next:REMIFENTANIL (cas 132875-61-7) attenuates lipopolysaccharide-induced oxidative injury by downregulating PKCβ2 activation and inhibiting autophagy in H9C2 cardiomyocytes) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Scientific ArticleREMIFENTANIL (cas 132875-61-7)–ketamine vs. propofol–ketamine for sedation in pediatric patients undergoing colonoscopy: A randomized clinical trialREMIFENTANIL (cas 132875-61-7)–cetamina vs. propofol–cetamina para sedação em pacientes pediátricos submetidos à colonoscopia: ensaio clínico randômico09/05/2019
- Clinical InformationSedation using dexmedetomidine and REMIFENTANIL (cas 132875-61-7) with local anesthesia for intraoperative speech monitoring: a case reportSedação com dexmedetomidina e REMIFENTANIL (cas 132875-61-7) em anestesia local para monitoração intraoperatória da fala: um relato de caso09/04/2019
- A physiologically-based model to predict individual pharmacokinetics and pharmacodynamics of REMIFENTANIL (cas 132875-61-7)09/03/2019
- REMIFENTANIL (cas 132875-61-7) attenuates lipopolysaccharide-induced oxidative injury by downregulating PKCβ2 activation and inhibiting autophagy in H9C2 cardiomyocytes09/02/2019
- Annexin 1 inhibits REMIFENTANIL (cas 132875-61-7)-induced hyperalgesia and NMDA receptor phosphorylation via regulating spinal CXCL12/CXCR4 in rats08/31/2019
- Research paperOptimized PID control of propofol and REMIFENTANIL (cas 132875-61-7) coadministration for general anesthesia08/30/2019
- Original ArticleREMIFENTANIL (cas 132875-61-7) patient-controlled intravenous analgesia during labour: a retrospective observational study of 10 years’ experience08/29/2019
- Original ArticleREMIFENTANIL (cas 132875-61-7) patient-controlled analgesia in labour: six-year audit of outcome data of the RemiPCA SAFE Network (2010–2015)08/28/2019
- Original ArticleSerious adverse events attributed to REMIFENTANIL (cas 132875-61-7) patient-controlled analgesia during labour in The Netherlands08/27/2019
